Mailed Self-Collection Kits: A Dual-Purpose Solution for Cervical Cancer and STI Screening in High-Risk Populations

Introduction: Bridging the Gap in Women’s Preventive Health

Despite the availability of highly effective screening tools for cervical cancer and sexually transmitted infections (STIs), significant disparities in health outcomes persist among women in the United States. Vulnerable populations—particularly low-income women, those living in rural areas, and those from marginalized racial and ethnic backgrounds—often face systemic barriers to traditional clinic-based screening. These barriers include lack of transportation, childcare responsibilities, limited health insurance coverage, and historical mistrust of the medical establishment.

Recent advancements in molecular diagnostics have introduced a potential game-changer: self-collection. While Human Papillomavirus (HPV) self-collection has already demonstrated its ability to increase cervical cancer screening uptake, its potential as a vehicle for broader STI screening remains underutilized. A new secondary analysis of the My Body, My Test-3 (MBMT-3) trial, published in JAMA Network Open, explores the clinical utility of streamlining STI testing alongside HPV screening through mailed self-collection kits.

The My Body, My Test-3 Study: A Strategic Analysis

Study Design and Population

The MBMT-3 study was a randomized clinical trial conducted between April 2016 and December 2019, targeting 22 counties in North Carolina. This specific secondary analysis focused on 327 participants randomized to the intervention group who provided valid results for both HPV and other STIs (chlamydia, gonorrhea, and trichomoniasis). The study population primarily consisted of low-income women who were overdue for cervical cancer screening, representing a high-risk cohort that frequently falls through the cracks of the traditional healthcare system.

The median age of the participants was 42 years. The cohort was racially diverse, with 44.7% identifying as non-Hispanic Black, 40.7% as non-Hispanic White, and 8.6% as Hispanic. By focusing on this specific demographic, the researchers aimed to evaluate whether a single self-collected sample could effectively address multiple preventive health needs simultaneously.

The Intervention: The Aptima Multitest Assay

Participants in the intervention group received a mailed self-collection kit containing a cervicovaginal swab and detailed instructions. The samples were returned via mail and analyzed using the Aptima assay, a highly sensitive and specific nucleic acid amplification test (NAAT). This streamlined approach allowed for the detection of high-risk HPV types as well as common bacterial STIs from the same specimen, minimizing the burden on the patient and the diagnostic laboratory.

Key Findings: Prevalence and Risk Profiles

High Yield for Undiagnosed Infections

The results of the analysis underscore the high burden of undiagnosed infections in this population. Among the 327 participants, 15.6% (n=51) tested positive for at least one STI other than HPV. Interestingly, the positivity rate for high-risk HPV was identical at 15.6% (n=51). Only 7 participants (2.1%) tested positive for both an STI and HPV, suggesting that screening for one does not necessarily capture the risk for the other, and that dual testing provides significant incremental value.

Identifying Clinical Risk Factors

The study conducted a rigorous risk factor analysis to identify which patients were most likely to benefit from this integrated screening approach. Several key predictors for testing positive for STIs emerged:

1. Race and Ethnicity: Non-Hispanic Black women had significantly higher odds of testing positive compared to non-Hispanic White women (adjusted Odds Ratio [aOR], 4.1; 95% CI, 1.5-11.6).
2. Sexual Behavior: Women who reported having two or more sexual partners in the past year were much more likely to have an STI compared to those with no partners (aOR, 5.7; 95% CI, 1.0-31.4).
3. Marital Status: Single women faced a higher risk compared to those who were married or partnered (aOR, 5.6; 95% CI, 1.1-27.9).
4. Lifestyle Factors: Current smokers were more likely to test positive than non-smokers (aOR, 4.1; 95% CI, 1.7-10.4).

These findings suggest that while all underscreened women benefit from access to self-collection, certain sociodemographic and behavioral factors can help clinicians and public health officials prioritize outreach efforts.

Patient Perspectives and the Path to Treatment

High Acceptability and Preference

For any screening intervention to be successful, it must be acceptable to the target population. The MBMT-3 analysis found that participants overwhelmingly supported the integrated testing model. Approximately 84.4% of participants reported a preference for dual testing (HPV and other STIs) in the future. This high level of acceptability suggests that self-collection reduces the psychological and logistical barriers associated with pelvic exams, which are often cited as a reason for avoiding screening.

The Challenge of Follow-up Care

Detection is only the first step in the clinical continuum. The study also tracked the rate of follow-up care among those who tested positive for an STI. While 66.7% of participants received the necessary follow-up care, one-third did not. This represents a significant challenge for clinicians. In a traditional clinic setting, treatment can often be initiated immediately following a positive result. In a mailed-screening model, the lag between testing and treatment requires robust navigation services to ensure patients are linked to care. The 66.7% follow-up rate is encouraging but highlights the need for integrated systems that bridge the gap between home-based testing and clinical intervention.

Expert Commentary: Implications for Clinical Practice

From a clinical and public health perspective, the MBMT-3 secondary analysis provides strong evidence for the “screen-and-treat” paradigm shift. By bundling STI and HPV testing, providers can capitalize on a single patient interaction—even a remote one—to address multiple health risks.

Biological Plausibility and Co-infection

The biological relationship between STIs and HPV is well-documented. Infections such as Chlamydia trachomatis can cause localized inflammation and mucosal damage, potentially facilitating the persistence or entry of high-risk HPV. While this study showed a low rate of co-infection (2.1%), the overall prevalence of both infection types in this cohort (over 30% combined) justifies the use of a broad-spectrum screening tool.

Addressing Health Inequities

This research is particularly relevant in the context of health equity. The disproportionate impact of STIs and cervical cancer on Black and low-income women is a result of structural inequities rather than biological predisposition. Mailed self-collection serves as a structural intervention that meets patients where they are, bypassing many of the barriers inherent in the U.S. healthcare system. For clinicians working in safety-net hospitals or community health centers, incorporating self-collection protocols could significantly improve screening rates and patient outcomes.

Conclusion: A Scalable Model for the Future

The secondary analysis of the My Body, My Test-3 trial demonstrates that streamlined STI and HPV testing via mailed self-collection is both feasible and highly effective. With nearly 1 in 6 women testing positive for an STI, and a similar number for HPV, the clinical yield of this intervention is substantial.

To maximize the impact of this model, future efforts should focus on:
1. Scaling Distribution: Partnering with state health departments and Medicaid programs to provide kits to underscreened populations.
2. Improving Linkage to Care: Developing automated or navigator-led systems to ensure that every positive result leads to timely treatment.
3. Policy Integration: Advocating for insurance reimbursement of self-collection kits as a standard of care for hard-to-reach populations.

By embracing these innovative diagnostic strategies, the medical community can take a significant step toward eliminating the disparities that have long defined women’s reproductive health.

Funding and Clinical Trial Information

This research was supported by grants from the National Institutes of Health (NIH) and the American Cancer Society. The parent trial, My Body, My Test-3, is registered at ClinicalTrials.gov under the identifier NCT02651883. The secondary analysis was conducted by researchers from the University of North Carolina at Chapel Hill and associated institutions.

References

1. Ganguly AP, Pretsch PK, Brewer NT, et al. Streamlined Self-Collection Screening for Sexually Transmitted Infections and Human Papillomavirus: A Single-Group Secondary Analysis of a Randomized Clinical Trial. JAMA Netw Open. 2026;9(1):e2551345.
2. Smith JS, Brewer NT, Chang Y, et al. Acceptance of self-collected samples for HPV testing among women who are underscreened. J Womens Health (Larchmt). 2016;25(11):1153-1162.
3. Des Marais AC, Zhao Y, Hudgens MG, et al. Mailed self-collection for HPV testing to increase cervical cancer screening: My Body, My Test-3 cluster randomized trial. BMJ. 2023;382:e073530.